Compare FSSL & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSSL | ARDX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 885.2M | 975.9M |
| IPO Year | 2025 | 2014 |
| Metric | FSSL | ARDX |
|---|---|---|
| Price | $11.62 | $3.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 228.7K | ★ 3.6M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | $9.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.75 | $3.68 |
| 52 Week High | $14.49 | $8.40 |
| Indicator | FSSL | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 27.70 |
| Support Level | $11.44 | N/A |
| Resistance Level | $11.83 | $6.47 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 31.33 | 9.72 |
FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing primarily in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest primarily in a portfolio of secured and unsecured floating and fixed rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.